{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:34:25Z","timestamp":1792978465310,"version":"4.5.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s12325-025-03256-x","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:22:06Z","timestamp":1748996526000},"page":"3606-3620","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Metformin: Old Drug, New Therapeutic Potential in the Skin? A Brief Narrative Review"],"prefix":"10.1007","volume":"42","author":[{"given":"Dimitrios","family":"Pantazopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Papachristou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanthia","family":"Gouveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Papi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Papazoglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7320-785X","authenticated-orcid":false,"given":"Nikolaos","family":"Papanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"issue":"Suppl 1","key":"3256_CR1","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.2337\/dc25-S009","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142025. Diabetes Care. 2025;48(Suppl 1):S181\u2013206.","journal-title":"Diabetes Care"},{"key":"3256_CR2","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.tips.2020.09.001","volume":"41","author":"L He","year":"2020","unstructured":"He L. Metformin and systemic metabolism. Trends Pharmacol Sci. 2020;41:868\u201381.","journal-title":"Trends Pharmacol Sci"},{"key":"3256_CR3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0140-6736(24)00537-3","volume":"404","author":"AI Adler","year":"2024","unstructured":"Adler AI, Coleman RL, Leal J, Whiteley WN, Clarke P, Holman RR. Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type\u00a02 diabetes extended from 10\u00a0years to 24\u00a0years (UKPDS 91). Lancet. 2024;404:145\u201355.","journal-title":"Lancet"},{"key":"3256_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s40200-023-01309-y","volume":"23","author":"M Bahardoust","year":"2024","unstructured":"Bahardoust M, Mousavi S, Yariali M, et al. Effect of metformin (vs placebo or sulfonylurea) on all-cause and cardiovascular mortality and incident cardiovascular events in patients with diabetes: an umbrella review of systematic reviews with meta-analysis. J Diabetes Metab Disord. 2024;23:27\u201338.","journal-title":"J Diabetes Metab Disord"},{"key":"3256_CR5","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1185\/03007995.2014.921608","volume":"30","author":"X Dai","year":"2014","unstructured":"Dai X, Wang H, Jing Z, Fu P. The effect of a dual combination of noninsulin antidiabetic drugs on lipids: a systematic review and network meta-analysis. Curr Med Res Opin. 2014;30:1777\u201386.","journal-title":"Curr Med Res Opin"},{"key":"3256_CR6","first-page":"CD008558","volume":"2019","author":"KS Madsen","year":"2019","unstructured":"Madsen KS, Chi Y, Metzendorf M-I, Richter B, Hemmingsen B. Metformin for prevention or delay of type\u00a02 diabetes mellitus and its associated complications in persons at increased risk for the development of type\u00a02 diabetes mellitus. Cochrane Database Syst Rev. 2019;2019:CD008558.","journal-title":"Cochrane Database Syst Rev"},{"key":"3256_CR7","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1042\/CS20110386","volume":"122","author":"B Viollet","year":"2012","unstructured":"Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 2012;122:253\u201370.","journal-title":"Clin Sci (Lond)"},{"key":"3256_CR8","doi-asserted-by":"publisher","first-page":"635","DOI":"10.3389\/fphar.2020.00635","volume":"11","author":"M Deng","year":"2020","unstructured":"Deng M, Su D, Xu S, et al. Metformin and vascular diseases: a focused review on smooth muscle cell function. Front Pharmacol. 2020;11:635.","journal-title":"Front Pharmacol"},{"key":"3256_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107585","volume":"213","author":"GG Chen","year":"2020","unstructured":"Chen GG, Woo PY, Ng SC, et al. Impact of metformin on immunological markers: implication in its anti-tumor mechanism. Pharmacol Ther. 2020;213:107585.","journal-title":"Pharmacol Ther"},{"key":"3256_CR10","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1136\/bmj.38415.708634.F7","volume":"330","author":"JM Evans","year":"2005","unstructured":"Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330:1304\u20135.","journal-title":"BMJ"},{"issue":"8","key":"3256_CR11","doi-asserted-by":"publisher","first-page":"713","DOI":"10.36849\/JDD.2020.4874","volume":"19","author":"CT Sung","year":"2020","unstructured":"Sung CT, Chao T, Lee A, et al. Oral metformin for treating dermatological diseases: a systematic review. J Drugs Dermatol. 2020;19(8):713\u201320.","journal-title":"J Drugs Dermatol"},{"key":"3256_CR12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3389\/fendo.2020.00191","volume":"11","author":"Z Lv","year":"2020","unstructured":"Lv Z, Guo Y. Metformin and its benefits for various diseases. Front Endocrinol (Lausanne). 2020;11:191.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3256_CR13","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1136\/bmj.293.6545.483","volume":"293","author":"L Klapholz","year":"1986","unstructured":"Klapholz L, Leitersdorf E, Weinrauch L. Leucocytoclastic vasculitis and pneumonitis induced by metformin. Br Med J (Clin Res Ed). 1986;293:483.","journal-title":"Br Med J (Clin Res Ed)"},{"key":"3256_CR14","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1345\/aph.1H155","volume":"40","author":"C Ben Salem","year":"2006","unstructured":"Ben Salem C, Hmouda H, Slim R, Denguezli M, Belajouza C, Bouraoui K. Rare case of metformin-induced leukocytoclastic vasculitis. Ann Pharmacother. 2006;40:1685\u20137.","journal-title":"Ann Pharmacother"},{"key":"3256_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2165\/11593230-000000000-00000","volume":"13","author":"T Czarnowicki","year":"2012","unstructured":"Czarnowicki T, Ramot Y, Ingber A, Maly A, Horev L. Metformin induced leukocytoclastic vasculitis: a case report. Am J Clin Dermatol. 2012;13:61\u20133.","journal-title":"Am J Clin Dermatol"},{"key":"3256_CR16","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1159\/000246152","volume":"194","author":"H Azzam","year":"1997","unstructured":"Azzam H, Bergman R, Friedman-Birnbaum R. Lichen planus associated with metformin therapy. Dermatology. 1997;194:376\u20137.","journal-title":"Dermatology"},{"key":"3256_CR17","first-page":"658","volume":"19","author":"H Nasri","year":"2014","unstructured":"Nasri H, Rafieian-Kopaei M. Metformin: current knowledge. J Res Med Sci. 2014;19:658\u201364.","journal-title":"J Res Med Sci"},{"key":"3256_CR18","doi-asserted-by":"publisher","first-page":"C873","DOI":"10.1152\/ajpcell.00604.2020","volume":"320","author":"LP Bharath","year":"2021","unstructured":"Bharath LP, Nikolajczyk BS. The intersection of metformin and inflammation. Am J Physiol Physiol. 2021;320:C873\u20139.","journal-title":"Am J Physiol Physiol"},{"key":"3256_CR19","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.cmet.2014.09.018","volume":"20","author":"M Foretz","year":"2014","unstructured":"Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: from mechanisms of action to therapies. Cell Metab. 2014;20:953\u201366.","journal-title":"Cell Metab"},{"key":"3256_CR20","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","volume":"60","author":"G Rena","year":"2017","unstructured":"Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60:1577\u201385.","journal-title":"Diabetologia"},{"key":"3256_CR21","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1007\/s00125-017-4336-x","volume":"60","author":"E Sanchez-Rangel","year":"2017","unstructured":"Sanchez-Rangel E, Inzucchi SE. Metformin: clinical use in type\u00a02 diabetes. Diabetologia. 2017;60:1586\u201393.","journal-title":"Diabetologia"},{"key":"3256_CR22","doi-asserted-by":"publisher","first-page":"8960","DOI":"10.3390\/ijms21238960","volume":"21","author":"JE Chang","year":"2020","unstructured":"Chang JE, Choi MS. A molecular perspective on the potential benefits of metformin for the treatment of inflammatory skin disorders. Int J Mol Sci. 2020;21:8960.","journal-title":"Int J Mol Sci"},{"key":"3256_CR23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.yexcr.2017.01.017","volume":"352","author":"MM Chung","year":"2017","unstructured":"Chung MM, Nicol CJ, Cheng YC, et al. Metformin activation of AMPK suppresses AGE-induced inflammatory response in hNSCs. Exp Cell Res. 2017;352:75\u201383.","journal-title":"Exp Cell Res"},{"key":"3256_CR24","doi-asserted-by":"publisher","first-page":"4847812","DOI":"10.1155\/2016\/4847812","volume":"2016","author":"Z Zhou","year":"2016","unstructured":"Zhou Z, Tang Y, Jin X, et al. Metformin inhibits advanced glycation end products-induced inflammatory response in murine macrophages partly through AMPK activation and RAGE\/Nf\u03bab pathway suppression. J Diabetes Res. 2016;2016:4847812.","journal-title":"J Diabetes Res"},{"key":"3256_CR25","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.3390\/ijms21051835","volume":"21","author":"A Poznyak","year":"2020","unstructured":"Poznyak A, Grechko AV, Poggio P, Myasoedova VA, Alfieri V, Orekhov AN. The diabetes mellitus-atherosclerosis connection: the role of lipid and glucose metabolism and chronic inflammation. Int J Mol Sci. 2020;21:1835.","journal-title":"Int J Mol Sci"},{"key":"3256_CR26","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/nature05488","volume":"444","author":"JP Despr\u00e9s","year":"2006","unstructured":"Despr\u00e9s JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444:881\u20137.","journal-title":"Nature"},{"key":"3256_CR27","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/iub.1966","volume":"71","author":"Q Zhang","year":"2019","unstructured":"Zhang Q, Ai Y, Dong H, Wang J, Xu L. Circulating oxidized low-density lipoprotein is a strong risk factor for the early stage of coronary heart disease. IUBMB Life. 2019;71:277\u201382.","journal-title":"IUBMB Life"},{"key":"3256_CR28","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.clindermatol.2004.03.004","volume":"22","author":"CC Zouboulis","year":"2004","unstructured":"Zouboulis CC. Acne and sebaceous gland function. Clin Dermatol. 2004;22:360\u20136.","journal-title":"Clin Dermatol"},{"key":"3256_CR29","doi-asserted-by":"publisher","first-page":"adv18392","DOI":"10.2340\/actadv.v103.18392","volume":"103","author":"M Cho","year":"2023","unstructured":"Cho M, Woo YR, Cho SH, Lee JD, Kim HS. Metformin: a potential treatment for acne, hidradenitis suppurativa and rosacea. Acta Derm Venereol. 2023;103:adv18392.","journal-title":"Acta Derm Venereol"},{"key":"3256_CR30","doi-asserted-by":"publisher","DOI":"10.1080\/19381980.2017.1356518","volume":"9","author":"Y Mirdamadi","year":"2017","unstructured":"Mirdamadi Y, Bommhardt U, Goihl A, et al. Insulin and insulin-like growth factor-1 can activate the phosphoinositide-3-kinase\/Akt\/FoxO1 pathway in T\u00a0cells in vitro. Dermatoendocrinology. 2017;9:e1356518.","journal-title":"Dermatoendocrinology"},{"key":"3256_CR31","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/j.1365-2133.2008.08764.x","volume":"159","author":"S Vora","year":"2008","unstructured":"Vora S, Ovhal A, Jerajani H, Nair N, Chakrabortty A. Correlation of facial sebum to serum insulin-like growth factor-1 in patients with acne. Br J Dermatol. 2008;159:990\u20131.","journal-title":"Br J Dermatol"},{"key":"3256_CR32","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1111\/jdv.12116","volume":"27","author":"D Badr","year":"2013","unstructured":"Badr D, Kurban M, Abbas O. Metformin in dermatology: an overview. J Eur Acad Dermatol Venereol. 2013;27:1329\u201335.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3256_CR33","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1530\/EJE-07-0294","volume":"157","author":"S Tan","year":"2007","unstructured":"Tan S, Hahn S, Benson S, et al. Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. Eur J Endocrinol. 2007;157:669\u201376.","journal-title":"Eur J Endocrinol"},{"key":"3256_CR34","first-page":"34","volume":"12","author":"S Sharma","year":"2019","unstructured":"Sharma S, Mathur DK, Paliwal V, Bhargava P. Efficacy of metformin in the treatment of acne in women with polycystic ovarian syndrome: a newer approach to acne therapy. J Clin Aesthet Dermatol. 2019;12:34\u20138.","journal-title":"J Clin Aesthet Dermatol"},{"key":"3256_CR35","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/ced.12673","volume":"41","author":"G Fabbrocini","year":"2016","unstructured":"Fabbrocini G, Izzo R, Faggiano A, et al. Low glycaemic diet and metformin therapy: a new approach in male subjects with acne resistant to common treatments. Clin Exp Dermatol. 2016;41:38\u201342.","journal-title":"Clin Exp Dermatol"},{"key":"3256_CR36","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1210\/jc.2011-1671","volume":"96","author":"L Ib\u00e1\u00f1ez","year":"2011","unstructured":"Ib\u00e1\u00f1ez L, Diaz M, Sebastiani G, et al. Treatment of androgen excess in adolescent girls: ethinylestradiol-cyproteroneacetate versus low-dose pioglitazone-flutamide-metformin. J Clin Endocrinol Metab. 2011;96:3361\u20136.","journal-title":"J Clin Endocrinol Metab"},{"key":"3256_CR37","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2165\/00128071-200405030-00008","volume":"5","author":"T Hermanns-L\u00ea","year":"2004","unstructured":"Hermanns-L\u00ea T, Scheen A, Pi\u00e9rard GE. Acanthosis nigricans associated with insulin resistance: pathophysiology and management. Am J Clin Dermatol. 2004;5:199\u2013203.","journal-title":"Am J Clin Dermatol"},{"key":"3256_CR38","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s42000-019-00130-8","volume":"18","author":"R Mourelatou","year":"2019","unstructured":"Mourelatou R, Kostopoulou E, Rojas-Gil AP, et al. Decreased adipocyte glucose transporter 4 (GLUT4) and aquaglyceroporin-7 (AQP7) in adults with morbid obesity: Possible early markers of metabolic dysfunction. Hormones. 2019;18:297\u2013306.","journal-title":"Hormones"},{"key":"3256_CR39","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13453","volume":"74","author":"NA \u00c1lvarez-Villalobos","year":"2020","unstructured":"\u00c1lvarez-Villalobos NA, Rodr\u00edguez-Guti\u00e9rrez R, Gonz\u00e1lez-Saldivar G, et al. Acanthosis nigricans in middle-age adults: a highly prevalent and specific clinical sign of insulin resistance. Int J Clin Pract. 2020;74:e13453.","journal-title":"Int J Clin Pract"},{"key":"3256_CR40","first-page":"E20","volume":"105","author":"L Bomar","year":"2020","unstructured":"Bomar L, Lewallen R, Jorizzo J. Localized acanthosis nigricans at the site of repetitive insulin injections. Cutis. 2020;105:E20\u20132.","journal-title":"Cutis"},{"key":"3256_CR41","doi-asserted-by":"publisher","first-page":"4","DOI":"10.4103\/0253-7613.174388","volume":"48","author":"AK Bubna","year":"2016","unstructured":"Bubna AK. Metformin\u2014for the dermatologist. Indian J Pharmacol. 2016;48:4\u201310.","journal-title":"Indian J Pharmacol"},{"key":"3256_CR42","doi-asserted-by":"publisher","first-page":"e281","DOI":"10.1111\/pde.13206","volume":"34","author":"D Giri","year":"2017","unstructured":"Giri D, Alsaffar H, Ramakrishnan R. Acanthosis nigricans and its response to metformin. Pediatr Dermatol. 2017;34:e281\u20132.","journal-title":"Pediatr Dermatol"},{"key":"3256_CR43","doi-asserted-by":"publisher","first-page":"115","DOI":"10.4103\/ijd.IJD_417_17","volume":"64","author":"A Sett","year":"2019","unstructured":"Sett A, Pradhan S, Sancheti K, et al. Effectiveness and safety of metformin versus Canthex\u2122 in patients with acanthosis nigricans: a randomized, double-blind controlled trial. Indian J Dermatol. 2019;64:115\u201321.","journal-title":"Indian J Dermatol"},{"key":"3256_CR44","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMcp1014163","volume":"366","author":"GB Jemec","year":"2012","unstructured":"Jemec GB. Clinical practice. Hidradenitis suppurativa. N Engl J Med. 2012;366:158\u201364.","journal-title":"N Engl J Med"},{"key":"3256_CR45","doi-asserted-by":"publisher","first-page":"601","DOI":"10.2340\/00015555-0749","volume":"89","author":"L Matusiak","year":"2009","unstructured":"Matusiak L, Bieniek A, Szepietowski JC. Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents? Acta Derm Venereol. 2009;89:601\u20133.","journal-title":"Acta Derm Venereol"},{"key":"3256_CR46","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1111\/j.1468-3083.2012.04668.x","volume":"27","author":"R Verdolini","year":"2013","unstructured":"Verdolini R, Clayton N, Smith A, Alwash N, Mannello B. Metformin for the treatment of hidradenitis suppurativa: a little help along the way. J Eur Acad Dermatol Venereol. 2013;27:1101\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3256_CR47","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1111\/j.1365-2230.2008.03121.x","volume":"34","author":"B Arun","year":"2009","unstructured":"Arun B, Loffeld A. Long-standing hidradenitis suppurativa treated effectively with metformin. Clin Exp Dermatol. 2009;34:920\u20131.","journal-title":"Clin Exp Dermatol"},{"key":"3256_CR48","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1159\/000473873","volume":"9","author":"BN Khandalavala","year":"2017","unstructured":"Khandalavala BN. A disease-modifying approach for advanced hidradenitis suppurativa (regimen with metformin, liraglutide, dapsone, and finasteride): a case report. Case Rep Dermatol. 2017;9:70\u20138.","journal-title":"Case Rep Dermatol"},{"key":"3256_CR49","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/09546634.2019.1592100","volume":"31","author":"L Jennings","year":"2020","unstructured":"Jennings L, Hambly R, Hughes R, Moriarty B, Kirby B. Metformin use in hidradenitis suppurativa. J Dermatol Treat. 2020;31:261\u20133.","journal-title":"J Dermatol Treat"},{"key":"3256_CR50","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1056\/NEJMra0804595","volume":"361","author":"FO Nestle","year":"2009","unstructured":"Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361:496\u2013509.","journal-title":"N Engl J Med"},{"key":"3256_CR51","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3389\/fimmu.2018.00579","volume":"9","author":"WH Boehncke","year":"2018","unstructured":"Boehncke WH. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences. Front Immunol. 2018;9:579.","journal-title":"Front Immunol"},{"key":"3256_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.605691","volume":"8","author":"V Brazzelli","year":"2021","unstructured":"Brazzelli V, Maffioli P, Bolcato V, et al. Psoriasis and diabetes, a dangerous association: evaluation of insulin resistance, lipid abnormalities, and cardiovascular risk biomarkers. Front Med (Lausanne). 2021;8: 605691.","journal-title":"Front Med (Lausanne)"},{"key":"3256_CR53","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1080\/09546634.2020.1826392","volume":"33","author":"L Lin","year":"2022","unstructured":"Lin L, Xu X, Yu Y, et al. Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type\u00a02 diabetes: a randomized-controlled trial. J Dermatol Treat. 2022;33:1428\u201334.","journal-title":"J Dermatol Treat"},{"key":"3256_CR54","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3390\/jpm11040251","volume":"11","author":"AMA Stanescu","year":"2021","unstructured":"Stanescu AMA, Simionescu AA, Florea M, Diaconu CC. Is metformin a possible beneficial treatment for psoriasis? A scoping review. J Pers Med. 2021;11:251.","journal-title":"J Pers Med"},{"key":"3256_CR55","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3892\/etm.2013.1416","volume":"7","author":"W Li","year":"2014","unstructured":"Li W, Ma W, Zhong H, Liu W, Sun Q. Metformin inhibits proliferation of human keratinocytes through a mechanism associated with activation of the MAPK signaling pathway. Exp Ther Med. 2014;7:389\u201392.","journal-title":"Exp Ther Med"},{"key":"3256_CR56","doi-asserted-by":"publisher","first-page":"611","DOI":"10.7326\/0003-4819-142-8-200504190-00009","volume":"142","author":"TJ Orchard","year":"2005","unstructured":"Orchard TJ, Temprosa M, Goldberg R, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005;142:611\u20139.","journal-title":"Ann Intern Med"},{"key":"3256_CR57","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/cbf.3367","volume":"37","author":"W Ba","year":"2019","unstructured":"Ba W, Xu Y, Yin G, et al. Metformin inhibits pro-inflammatory responses via targeting nuclear factor-\u03baB in HaCaT\u00a0cells. Cell Biochem Funct. 2019;37:4\u201310.","journal-title":"Cell Biochem Funct"},{"key":"3256_CR58","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.jaad.2007.11.023","volume":"58","author":"YB Brauchli","year":"2008","unstructured":"Brauchli YB, Jick SS, Curtin F, Meier CR. Association between use of thiazolidinediones or other oral antidiabetics and psoriasis: a population based case\u2013control study. J Am Acad Dermatol. 2008;58:421\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"3256_CR59","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12895-016-0049-y","volume":"16","author":"S Singh","year":"2016","unstructured":"Singh S, Bhansali A. Randomized placebo control study of insulin sensitizers (metformin and pioglitazone) in psoriasis patients with metabolic syndrome (topical treatment cohort). BMC Dermatol. 2016;16:12.","journal-title":"BMC Dermatol"},{"key":"3256_CR60","doi-asserted-by":"publisher","first-page":"581","DOI":"10.4103\/ijem.IJEM_46_17","volume":"21","author":"S Singh","year":"2017","unstructured":"Singh S, Bhansali A. Randomized placebo control study of metformin in psoriasis patients with metabolic syndrome (systemic treatment cohort). Ind J Endocrinol Metab. 2017;21:581\u20137.","journal-title":"Ind J Endocrinol Metab"},{"key":"3256_CR61","doi-asserted-by":"publisher","first-page":"9838867","DOI":"10.1155\/2022\/9838867","volume":"2022","author":"HTX Tam","year":"2022","unstructured":"Tam HTX, Thuy LND, Vinh NM, Anh TN, Van BT. The combined use of metformin and methotrexate in psoriasis patients with metabolic syndrome. Dermatol Res Pract. 2022;2022:9838867.","journal-title":"Dermatol Res Pract"},{"key":"3256_CR62","doi-asserted-by":"publisher","first-page":"606","DOI":"10.5114\/ada.2023.130524","volume":"40","author":"Z Huang","year":"2023","unstructured":"Huang Z, Li J, Chen H, Yu D, Sun S. The efficacy of metformin for the treatment of psoriasis: a meta-analysis study. Postepy Dermatol Alergol. 2023;40:606\u201310.","journal-title":"Postepy Dermatol Alergol"},{"issue":"Suppl 2","key":"3256_CR63","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1136\/annrheumdis-2014-eular.2756","volume":"73","author":"A Abou-Raya","year":"2014","unstructured":"Abou-Raya A, Abou-Raya S, Helmii M. SAT0384 metformin: a valid add-on drug in the treatment of psoriatic arthritis\u2014randomized controlled trial. Ann Rheum Dis. 2014;73(Suppl 2):733.","journal-title":"Ann Rheum Dis"},{"key":"3256_CR64","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/nm1616","volume":"13","author":"K Yamasaki","year":"2007","unstructured":"Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007;13:975\u201380.","journal-title":"Nat Med"},{"issue":"11","key":"3256_CR65","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1038\/jid.2014.222","volume":"134","author":"Y Muto","year":"2014","unstructured":"Muto Y, Wang Z, Vanderberghe M, Two A, Gallo RL, Di Nardo A. Mast cells are key mediators of cathelicidin-initiated skin inflammation in rosacea. J Investig Dermatol. 2014;134(11):2728\u201336.","journal-title":"J Investig Dermatol"},{"key":"3256_CR66","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1093\/cvr\/cvp131","volume":"83","author":"BK Tan","year":"2009","unstructured":"Tan BK, Adya R, Chen J, et al. Metformin decreases angiogenesis via NF-kappaB and Erk1\/2\/Erk5 pathways by increasing the antiangiogenic thrombospondin-1. Cardiovasc Res. 2009;83:566\u201374.","journal-title":"Cardiovasc Res"},{"key":"3256_CR67","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.biopha.2009.08.004","volume":"64","author":"DO Xavier","year":"2010","unstructured":"Xavier DO, Amaral LS, Gomes MA, et al. Metformin inhibits inflammatory angiogenesis in a murine sponge model. Biomed Pharmacother. 2010;64:220\u20135.","journal-title":"Biomed Pharmacother"},{"key":"3256_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105971","volume":"174","author":"Y Li","year":"2021","unstructured":"Li Y, Yang L, Wang Y, et al. Exploring metformin as a candidate drug for rosacea through network pharmacology and experimental validation. Pharmacol Res. 2021;174:105971.","journal-title":"Pharmacol Res"},{"key":"3256_CR69","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.cpt.2024.08.002","volume":"3","author":"AH Roky","year":"2024","unstructured":"Roky AH, Islam MM, Ahasan AMF, et al. Overview of skin cancer types and prevalence rates across continents. Cancer Pathog Ther. 2024;3:89\u2013100.","journal-title":"Cancer Pathog Ther"},{"key":"3256_CR70","first-page":"207","volume":"60","author":"E Giovannucci","year":"2010","unstructured":"Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. CA Cancer J Clin. 2010;60:207\u201321.","journal-title":"CA Cancer J Clin"},{"key":"3256_CR71","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.2337\/dc08-2175","volume":"32","author":"G Libby","year":"2009","unstructured":"Libby G, Donnelly LA, Donnan PT, et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type\u00a02 diabetes. Diabetes Care. 2009;32:1620\u20135.","journal-title":"Diabetes Care"},{"key":"3256_CR72","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1093\/annonc\/mdw410","volume":"27","author":"C Coyle","year":"2016","unstructured":"Coyle C, Cafferty FH, Vale C, Langley RE. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann Oncol. 2016;27:2184\u201395.","journal-title":"Ann Oncol"},{"key":"3256_CR73","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3389\/fendo.2018.00472","volume":"9","author":"E Jaune","year":"2018","unstructured":"Jaune E, Rocchi S. Metformin: focus on melanoma. Front Endocrinol (Lausanne). 2018;9:472.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3256_CR74","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/pcmr.12576","volume":"30","author":"H Montaudi\u00e9","year":"2017","unstructured":"Montaudi\u00e9 H, Cerezo M, Bahadoran P, et al. Metformin monotherapy in melanoma: a pilot, open-label, prospective, and multicentric study indicates no benefit. Pigment Cell Melanoma Res. 2017;30:378\u201380.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"1","key":"3256_CR75","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/1940-6207.CAPR-13-0110","volume":"7","author":"LA Checkley","year":"2014","unstructured":"Checkley LA, Rho O, Angel JM, et al. Metformin inhibits skin tumor promotion in overweight and obese mice. Cancer Prev Res (Phila). 2014;7(1):54\u201364.","journal-title":"Cancer Prev Res (Phila)"},{"key":"3256_CR76","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.36849\/JDD.8249","volume":"23","author":"Z Haq","year":"2024","unstructured":"Haq Z, Mirza FN, Abdi P, Diaz MJ, Libby TJ. Metformin use and risk of non-melanoma skin cancer: a propensity-matched case\u2013control study. J Drugs Dermatol. 2024;23:1089\u201395.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"3256_CR77","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1158\/1940-6207.CAPR-20-0376","volume":"14","author":"MS Chang","year":"2021","unstructured":"Chang MS, Hartman RI, Xue J, Giovannucci EL, Nan H, Yang K. Risk of skin cancer associated with metformin use: a meta-analysis of randomized controlled trials and observational studies. Cancer Prev Res (Phila). 2021;14(1):77\u201384.","journal-title":"Cancer Prev Res (Phila)"},{"issue":"4","key":"3256_CR78","first-page":"185","volume":"64","author":"NN Do","year":"2016","unstructured":"Do NN, Eming SA. Skin fibrosis: models and mechanisms. Curr Res Transl Med. 2016;64(4):185\u201393.","journal-title":"Curr Res Transl Med"},{"key":"3256_CR79","doi-asserted-by":"publisher","first-page":"8633","DOI":"10.4049\/jimmunol.181.12.8633","volume":"181","author":"D Sag","year":"2008","unstructured":"Sag D, Carling D, Stout RD, Suttles J. Adenosine 5\u2032-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J Immunol. 2008;181:8633\u201341.","journal-title":"J Immunol"},{"key":"3256_CR80","doi-asserted-by":"publisher","DOI":"10.1111\/iwj.14345","volume":"21","author":"FK Tombulturk","year":"2024","unstructured":"Tombulturk FK, Soydas T, Kanigur-Sultuybek G. Topical metformin accelerates wound healing by promoting collagen synthesis and inhibiting apoptosis in a diabetic wound model. Int Wound J. 2024;21:e14345.","journal-title":"Int Wound J"},{"key":"3256_CR81","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s11033-021-06843-7","volume":"49","author":"FK Tombulturk","year":"2022","unstructured":"Tombulturk FK, Todurga-Seven ZG, Huseyinbas O, et al. Topical application of metformin accelerates cutaneous wound healing in streptozotocin-induced diabetic rats. Mol Biol Rep. 2022;49:73\u201383.","journal-title":"Mol Biol Rep"},{"key":"3256_CR82","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.3390\/cells11244094","volume":"11","author":"L Shi","year":"2022","unstructured":"Shi L, Jiang Z, Li J, et al. Metformin improves burn wound healing by modulating microenvironmental fibroblasts and macrophages. Cells. 2022;11:4094.","journal-title":"Cells"},{"key":"3256_CR83","first-page":"233","volume":"13","author":"M Karimipour","year":"2022","unstructured":"Karimipour M, Farjah GH, Hassanzadeh M, Zirak JM. Post-treatment with metformin improves random skin flap survival through promoting angiogenesis in rats. Vet Res Forum. 2022;13:233\u20139.","journal-title":"Vet Res Forum"},{"key":"3256_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2024.111188","volume":"401","author":"Y Chen","year":"2024","unstructured":"Chen Y, Cheng R, Lu W, et al. Metformin promotes the survival of random skin flaps via the activation of Nrf2\/HO-1 signaling. Chem Biol Interact. 2024;401:111188.","journal-title":"Chem Biol Interact"},{"key":"3256_CR85","doi-asserted-by":"publisher","first-page":"912","DOI":"10.3390\/ph15080912","volume":"15","author":"V Sorrenti","year":"2022","unstructured":"Sorrenti V, Benedetti F, Buriani A, et al. Immunomodulatory and antiaging mechanisms of resveratrol, rapamycin, and metformin: focus on mTOR and AMPK signaling networks. Pharmaceuticals (Basel). 2022;15:912.","journal-title":"Pharmaceuticals (Basel)"},{"key":"3256_CR86","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1007\/s12325-023-02434-z","volume":"40","author":"E Gouveri","year":"2023","unstructured":"Gouveri E, Papanas N. \u03a4he endless beauty of metformin: does it also protect from skin aging? A narrative review. Adv Ther. 2023;40:1347\u201356.","journal-title":"Adv Ther"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03256-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03256-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03256-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T18:46:27Z","timestamp":1757184387000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03256-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":86,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3256"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03256-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"assertion":[{"value":"29 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dimitrios Pantazopoulos, Stella Papachristou and Massimo Papi have no conflicts of interest. Evanthia Gouveri has attended conferences sponsored by Berlin-Chemie, Sanofi, AstraZeneca, Novo Nordisk, Lilly and Boehringer Ingelheim; received speaker honoraria by Boehringer Ingelheim and Menarini. Dimitrios Papazoglou declares associations with Menarini, Novo Nordisk, AstraZeneca, Boehringer Ingelheim and Sanofi-Aventis. Nikolaos Papanas has been an advisory board member of AstraZeneca, Bayer, Boehringer Ingelheim, Menarini, MSD, Novo Nordisk, Pfizer, Takeda and TrigoCare International; has participated in sponsored studies by AstraZeneca, Eli Lilly, GSK, MSD, Novo Nordisk, Novartis and Sanofi-Aventis; has received honoraria as a speaker for AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Elpen, Menarini, MSD, Mylan, Novo Nordisk, Pfizer, Sanofi-Aventis and Vianex; and has attended conferences sponsored by TrigoCare International, Bayer, Eli Lilly, Galenica, Novo Nordisk, Pfizer and Sanofi-Aventis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This review is based on previously conducted studies and meta-analyses and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}